The Management Board of Selvita S.A. with its registered office in Krakow (“Issuer”), hereby informs that Issuer’s Supervisory Board, acting pursuant to art. 368 par. 4 of the Polish Commercial Companies Code, appointed on January 31st, 2022 Ms. Adrijana Vinter the Management Board Member of the Issuer, effective February 1st, 2022.

Ms. Adrijana Vinter currently holds the position of Managing Director of Fidelta d.o.o., based in Croatia, a subsidiary of the Issuer. Joining the Issuer’s Management Board, Ms. Vinter will be responsible for overseeing the drug discovery services provided across the Issuer’s group. Information regarding the education, qualifications and positions previously held by Ms. Adrijana Vinter, along with her past job experience, is attached to this report.

Ms. Adrijana Vinter is not listed in the Registry of Insolvent Debtors maintained on the basis of the National Court Registry act, does not engage in competition with Selvita S.A, is not a partner in civil law partnerships or limited companies which engage in such competition and is not a member of any official bodies or other legal entities which engage in such competition, except for holding office in Fidelta d.o.o.

Moreover, the Management Board of the Issuer informs that it has received a statement on resignation of Ms. Edyta Jaworska from the position of the Member of the Management Board, without specifying reasons thereof, effective January 31, 2022.

Legal basis: Art. 56 section 1 item 2 of the Act on Public Offering – current and periodic information in connection with par. 5 points 4 and 5 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and conditions for recognising as equivalent information required by the laws of a non-member state (Journal of Laws of 2018, item 757)

Representatives of the Issuer:     

  • Bogusław Sieczkowski – President of the Management Board
  • Dawid Radziszewski – Management Board Member